6533b852fe1ef96bd12ab8e5
RESEARCH PRODUCT
A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Beatriz Guglieri-lópezRafael Ferriols-lisartAlejandro Pérez-pitarchMatilde Merino-sanjuánsubject
MaleMicrobiology (medical)OncologyLedipasvirSimeprevirmedicine.medical_specialtyPyrrolidinesDaclatasvirSofosbuvirHepatitis C virusPopulationHepacivirusPharmacologymedicine.disease_causeAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSimeprevirInternal medicinemedicineHepatitis C virus Meta-analysis Modelling Simulation SofosbuvirHumansPharmacology (medical)030212 general & internal medicineeducationFluoreneseducation.field_of_studybusiness.industryImidazolesValineGeneral MedicineHepatitis C ChronicModels TheoreticalClinical trialInfectious DiseaseschemistryMeta-analysisBenzimidazolesDrug Therapy CombinationFemale030211 gastroenterology & hepatologyCarbamatesSofosbuvirbusinessmedicine.drugdescription
The objective of this study was to compare the efficacy of sofosbuvir-based treatments in patients with chronic hepatitis C virus (HCV) infection using a model-based meta-analysis (MBMA). A bibliographic search was performed to identify clinical trials involving sofosbuvir as a unique direct-acting antiviral (DAA) agent or together with daclatasvir, ledipasvir or simeprevir for the treatment of diagnosed HCV infection. The time course of the virological response (VR) was modelled to estimate the effect of treatment and the influence of population characteristics on the longitudinal efficacy profile. The model was validated and simulations of 10 different treatment schedules were performed. Data from 19 clinical trials were included in the analysis. According to the developed model, therapy with sofosbuvir+ledipasvir is the most effective therapy in all scenarios, but it does not differ greatly in terms of sustained VR with respect to other combinations of DAA treatments. In conclusion, this MBMA generates knowledge regarding hypothetical head-to-head trials that have not been conducted previously. Therapies with sofosbuvir+ledipasvir are probably the most effective sofosbuvir-based treatments.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-01-01 |